NEW YORK, NY / ACCESSWIRE / November 24, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a ...

Humacyte Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of 0.00% with a gross margin of -41.67%. The profit margin, also known as the revenue ...

"The allegations in the complaint highlight serious violations of securities laws. If proven true, Humacyte's alleged failure to disclose material information to investors is unacceptable," said Reed ...

On Thursday, Humacyte Inc (HUMA) stock saw a decline, ending the day at $4.84 which represents a decrease of $-0.50 or -9.36% from the prior close of $5.34. The stock opened at $5.41 and touched a low ...

Insiders who acquired US$775.1k worth of Humacyte, Inc.'s ( NASDAQ:HUMA ) stock at an average price of US$6.64 in ...

Humacyte (HUMA) has disclosed a new risk, in the Share Price & Shareholder Rights category. Humacyte is facing substantial ...

Kathleen Sebelius, a director at Humacyte ($HUMA), sold 1,548 shares of the company on 09-10-2024. We received data on the trade from a recent SEC filing. This was a ...

Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ETCompany ParticipantsLauren Marek - LifeSci AdvisorsLaura Niklason ...

In the latest market close, Humacyte, Inc. (HUMA) reached $5.05, with a -1.94% movement compared to the previous day. The stock's change was less than the S&P 500's daily loss of 1.86%.